Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects
|
|
- Bryce Barrett
- 6 years ago
- Views:
Transcription
1 Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects MC. Rouan, J. Snoeys, S. Ouwerkerk-Mahadevan, R. Verloes, K. Marien, L. Vijgen, A. Vandebosch, P. Van Remoortere, P. De Doncker and K. Simmen Janssen Infectious Diseases, Beerse, Belgium and Titusville, USA 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy Cambridge MA, USA June 2013
2 Background-1 Simeprevir a potent hepatitis C virus (HCV) NS3/4A protease inhibitor in Phase 3 development TMC a potent novel HCV nonnon-nucleoside NS5B polymerase inhibitor coadministered with ritonavir in phase 2 studies 2
3 Background-2 Simeprevir 150 mg qd + TMC mg bid have been co-administered to HCV genotype 1 infected patients for 10 days 1 The combination was safe and well tolerated A potent antiviral activity was observed TMC exposure was increased by simeprevir (AUC about 2-fold ) Exposure decreased with repeated dosing for both compounds 1. Bourgeois S, et al. EASL, Amsterdam,
4 Why is TMC administered with ritonavir? TMC Substrate for CYP3A4 and P-gp Inducer of CYP3A4 (4β-hydroxy cholesterol plasma concentrations indicated TMC dose dependent induction) Reduces its exposure and that of simeprevir (substrate for CYP3A4) upon repeated dosing Ritonavir (low dose < 100 mg qd) Strong inhibitor of CYP3A4-mediated metabolism 1,2,3 Inhibitor of P-gp transport (clinical significance P-gp << CYP3A4 ) 3 CYP3A4 induction by TMC offset with ritonavir low dose <100 mg? 1. Mathias AA, et al. Clin Pharmacol Ther Jan;85(1): Eichbaum C, et al. Eur J Clin Pharmacol. Published online: 09 June Ieiri I, et al. J Clin Pharmacol Jun;53(6):
5 Doses anticipation using PBPK modeling PBPK modeling to predict dose levels Building PBPK models* for the three components (simeprevir, TMC647055, ritonavir) DDI # PBPK prediction considering CYP3A4-mediated interactions in the gut and the liver Target exposures for the combination simeprevir + TMC647055/r Simeprevir: exposure at 150 mg qd alone (current phase 3 trials) TMC647055: exposure at 1000 mg bid alone (monotherapy data) Clinical DDI study in healthy subjects to refine the doses to be given in a 12-week study in HCV-infected patients *: Physiologically Based Pharmacokinetic models (Simcyp simulator) # : Drug Drug Interaction 5
6 Simulating the past: simeprevir CYP3A4 inhibition Simeprevir-ritonavir DDI in healthy subjects 1 simeprevir 200 mg qd alone or with ritonavir 100 mg bid for 7 days CYP3A4 induction Simeprevir-efavirenz DDI in healthy subjects 2 simeprevir 150 mg qd alone or with efavirenz 600 mg qd for 14 days Effect of ritonavir on simeprevir Ratio with/without Observed Predicted* (PBPK) C max AUC 0-24h Effect of efavirenz on simeprevir Ratio with/without Observed Predicted* (PBPK) C max AUC 0-24h *: Virtual trial in healthy subjects 1. Sekar V, et al. EASL, Vienna, Ouwerkerk-Mahadevan S, et al. CROI, Seattle, Washington,
7 Simulating the past: dual combination 150 mg qd simeprevir mg bid TMC in HCV-infected patients for 10 days Simulated average plasma concentration-time profiles Simeprevir TMC Simeprevir Observed Predicted* C max (ng/ml) Mean parameters (CV%) observed and predicted on Day (37) 1300 (79) TMC Observed Predicted* C max (ng/ml) (40) 8200 (48) AUC 0-24h (ng.h/ml) (46) (97) AUC 0-12h (ng.h/ml) (45) (62) *: Virtual trial in HCV-infected patients. TMC PBPK predictions were adjusted for the effect of simeprevir not incorporated in the current model (2-fold increase in exposure) 7
8 Simulating the unknown 50 mg qd simeprevir, 300 mg qd TMC647055, 20 mg qd ritonavir is predicted to result in exposures close to targets Simulated average plasma concentration-time profiles* Simeprevir TMC *: Virtual trial in healthy subjects. TMC PBPK predictions were adjusted for the effect of simeprevir not incorporated in the current model (2-fold increase in exposure) 8
9 Clinical study in healthy subjects: study design Period 1 Simeprevir 150 mg Period 2 Simeprevir 50 mg TMC mg Ritonavir 20 mg 7-day washout 14 days 14 days 21-day washout Period 3 Simeprevir 100 mg TMC mg Ritonavir 30 mg 14 days qd administration of the three compounds after breakfast. Blood PK sampling on Day 14 Open-label, sequential study design consisting of 3 treatment periods separated by a washout period (n = 10 adult healthy subjects) Compare exposure of simeprevir and TMC when administered together with ritonavir at doses predicted using PBPK (Period 2) and at doses defined after interim analysis of previous study data (Period 3) to the target exposures (simeprevir: 150 mg qd alone, Period 1; TMC647055: 1000 mg bid alone, historical data) Assess the safety and tolerability of multiple doses of simeprevir +TMC647055/r
10 Results: TMC pharmacokinetics Mean TMC plasma profiles and PK parameters at 300 mg qd with 50 mg qd simeprevir + 20 mg qd ritonavir at 1000 mg bid alone (historical data) Mean (CV%) C max ng/ml AUC 24h ng.h/ml C min * ng/ml Combo 300 mg qd Day (60) (56) 210 (86) Alone 1000 mg bid historical data Day (27) (33) 160 (42) *: C 12h for bid dosing and C 24h for qd dosing 10
11 Results: simeprevir pharmacokinetics Mean simeprevir plasma profiles on Day 14 at 150 mg qd alone at 50 mg with 300 mg qd TMC mg ritonavir at 100 mg with 600 mg qd TMC mg ritonavir 11
12 Conclusions PBPK predictions allowed informed selection of appropriate doses to be tested in healthy volunteers The CYP3A4 inducing effect of TMC was counteracted by low-dose ritonavir. This enabled qd dosing of TMC Co-administration of simeprevir and TMC647055/r was safe and well tolerated in healthy subjects A trial in HCV-infected patients is ongoing with 12-week co-administration of simeprevir and TMC647055/r at doses derived from the exposures obtained in healthy subjects 12
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationCase #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals
Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationDRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR Pharmacology NS3/4A protease inhibitor NS5A inhibitor Adult Dose Investigational: 100 mg once daily Investigational: 50 mg once daily Being developed as
More informationPoster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA
Poster O_16 Lack of PK Interaction Between the HCV Protease Inhibitor MK-5172 and Methadone and Buprenorphine/Naloxone in Subjects on Stable Opiate Maintenance Therapy Iain Fraser, 1 Wendy W. Yeh, 1 Christina
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationEffect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
More informationBristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014
Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters Timothy Eley 15th HIV/HEPPK Workshop 21 May 2014 Disclosures T Eley is a full time employee and stockholder of Bristol-Myers
More informationSimeprevir (Olysio) Drug Summary. Class and Mechanism. Table of Contents
Hepatitis C Online PDF created September 18, 2018, 1:01 pm Simeprevir (Olysio) Table of Contents Simeprevir Olysio Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost
More informationApplication of PBPK Modeling and Simulations in Drug Development
Application of PBPK Modeling and Simulations in Drug Development Ping Zhao Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationThe effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates
The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates Varun Garg, PhD On behalf of Drs. N Adda, K Alves, G Chandorkar, J-E Lee, X Luo, F Smith, R van Heeswijk, and Y Yang Author
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationErik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs Erik Mogalian, Polina German, Chris Yang, Lisa
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationHerta Crauwels, et al.: Rilpivirine Drug-Drug Interactions
AIDS Rev. 2013;15:87 101 Herta Crauwels, et al.: Rilpivirine Drug-Drug Interactions Clinical Perspective on Drug Drug Interactions with the Non-nucleoside Reverse Transcriptase Inhibitor Rilpivirine Herta
More informationProfessor David Back
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor David Back University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationJennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) Jennifer R
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationCO-ADMINISTRATION WITH GRAZOPREVIR AND ELBASVIR HAS NO EFFECT ON PRAVASTATIN EXPOSURE BUT INCREASES ROSUVASTATIN EXPOSURE IN HEALTHY SUBJECTS
CO-ADMINISTRATION WITH GRAZOPREVIR AND ELBASVIR HAS NO EFFECT ON PRAVASTATIN EXPOSURE BUT INCREASES ROSUVASTATIN EXPOSURE IN HEALTHY SUBJECTS Luzelena Caro 1, William L. Marshall 1, Hwa-Ping Feng 1, Zifang
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Jefferies Health Care Conference June 2013 Charlotte Edenius, EVP Development
More informationPharmacologic Considerations when using DAAs in Cirrhosis
Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant
More informationAbstract ORIGINAL ARTICLE
Received: 27 February 218 Accepted: 4 March 218 DOI: 1.12/prp2.395 ORIGINAL ARTICLE Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir,
More informationReviews JOURNAL OF ABSTRACTS AND CONFERENCE REPORTS FROM INTERNATIONAL WORKSHOPS ON INFECTIOUS DISEASES & ANTIVIRAL THERAPY
E AL TH R IN CT IO U S DIS S SE IN FE EA Reviews & in Antiviral Therapy INFECTIOUS DISEASES 6 203 IN VIR PY A TI A N & REVIEWS JOURNAL OF ABSTRACTS AND CONFERENCE REPORTS FROM INTERNATIONAL WORKSHOPS ON
More informationDrug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals
Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals Polina German, Philip S Pang, Steve West, Lingling Han, Karim Sajwani and Anita Mathias Gilead
More information17 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 10, 2016 Washington, DC
MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients Nancy Kim 1 *, Wei Gao 1, Xiaoli Shirley
More informationEffect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
More informationDRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE
DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,
More informationT Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz
IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationEfficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus Infected Patients Following TMC435 Monotherapy
GASTROENTEROLOGY 212;143:1176 1178 BRIEF REPORTS Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus Infected Patients Following TMC435 Monotherapy OLIVER LENZ,* JOEP DE BRUIJNE,
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationEVALUATION OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSIOLOGICALLY- BASED PHARMACOKINETIC MODEL
Drug metabolism and Pharmacokinetics/PK Sciences EVALUATIN F DRUG-DRUG INTERACTIN PTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSILGICALLY- BASED PHARMACKINETIC MDEL Imad Hanna,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationMerck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. 8 th International Workshop on Clinical Pharmacology of Hepatitis Therapy June 2013
Relationship Between Transaminase Levels and Plasma Pharmacokinetics Following Administration of with Pegylated Interferon Alfa-2b and Ribavirin to G1 Treatment-Naïve HCV Patients Luzelena Caro, Lihong
More informationPharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationSelected Properties of Ledipasvir
Selected Properties of Ledipasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Harvoni (ledipasvir and sofosbuvir), GS-5885 Glilead Ledipasvir prevents replication
More informationPharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for. Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors
AAC Accepts, published online ahead of print on 2 April 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.06283-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Pharmacokinetic/Pharmacodynamic
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationPrediction of DDIs Arising from CYP3A Induction Using a Physiologically-based Dynamic Model. Lisa Almond 22 nd June 2016
Prediction of DDIs Arising from CYP3A Induction Using a Physiologically-based Dynamic Model Lisa Almond 22 nd June 2016 Growing impact of PBPK on drug labels Revatio (Sildenafil) Pulmonary Arterial Hypertension
More informationSlide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationPharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir
American Journal of Transplantation 2015; 15: 1313 1322 Wiley Periodicals Inc. C 2015 The Authors. American Journal of Transplantation Published by The American Society of Transplantation and the American
More informationUPDATES IN HEPATITIS C
UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationCurrent Drugs: Drug-Drug Interactions
Slide 1 Current Drugs: Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool May 2013 Toxicity HCV med Comed Reduced Efficacy The major effect of DAAs is to increase
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationDrug-Drug Interactions that Matter
Perspective Drug-Drug Interactions that Matter It is increasingly difficult to keep track of information on drug-drug interactions in HIV therapeutics, and the clinical implications of much of the data
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationFDA Use of Big Data in Modeling and Simulations
FDA Use of Big Data in Modeling and Simulations Jeffry Florian, Ph.D., Division of Pharmacometrics, CDER/OTS/OCP/DPM DISCLAIMER: The views expressed in this presentation are that of the author and do not
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationRedefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S
Redefining The Math 12 24 WEEKS W EE K S Hepatitis C; the most notorious of all hepatitis infections, has becoming a world threat due to its high morbidity and mortality rate. Moreover, with the prevalence
More informationPhysiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/08/31/dmd.117.076455.dc1 1521-009X/45/11/1156 1165$25.00 https://doi.org/10.1124/dmd.117.076455 DRUG
More informationThe Effect of Mild and Moderate Hepatic Impairment on Telaprevir Pharmacokinetics
The Effect of Mild and Moderate Hepatic Impairment on Telaprevir Pharmacokinetics B Adiwijaya, G Chandorkar, R van Heeswijk, L McNair, PY Kwo, S Gordon, and V Garg 6 th International Workshop on the Clinical
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 06.18
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: 01.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationTherapeutic Drug Monitoring in Antifungal Therapy. Why, When and How
Therapeutic Drug Monitoring in Antifungal Therapy Why, When and How Roger Brüggemann Radboud University Nijmegen Medical Centre and Nijmegen Institute for Infection, Inflammation and Immunology (N4i) Trends
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationUsing virtual populations to solve drug development problems. Iain Gardner Head of Translational DMPK Science SIMCYP
Using virtual populations to solve drug development problems Iain Gardner Head of Translational DMPK Science SIMCYP Prediction of human PK (PD) in virtual individuals In vitro system In vitro CLu int Scaling
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationMedivir at. Avanza s Företagsdag 10 december Lars Adlersson, CEO Börje Darpö, VP Development
Medivir at Avanza s Företagsdag 10 december 2008 Lars Adlersson, CEO Börje Darpö, VP Development Medivir contact rein.piir@medivir.se www.medivir.com Medivir Key achievements 2008 Strong phase IIa data
More informationSelected Properties of Rilpivirine. Edurant, TMC-278
Selected Properties of Rilpivirine Other names Manufacturer Pharmacology/Mechanism of Action Activity Edurant, TMC-278 Combination formulation: Complera : Emtricitabine/rilpivirine/tenofovir (marketed
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More information2018 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1127-9 Program Prior Authorization/Notification Medication Sovaldi (sofosbuvir) P&T Approval Date 2/2014, 4/2014, 5/2014, 8/2014,
More informationHandelsbanken November Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR
Handelsbanken November 18 2009 Bertil Samuelsson VP Discovery Research Rein Piir CFO / IR Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's markets ve phase
More informationPopulation pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure
Population pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure Elin M Svensson 1 Kelly E Dooley 2, Francesca Aweeka 3, Jeong-Gun Park 4, Mats
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors
More informationUpdates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today
Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since
More informationSingle-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men
Citation: Clin Transl Sci (2017) 10, 480 486; C 2017 ASCPT. All rights reserved doi:10.1111/cts.12482 ARTICLE Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men LCaro 1, J de Hoon
More informationSEVERE LIVER DISEASES & HIV INFECTION
SEVERE LIVER DISEASES & HIV INFECTION SEVERE LIVER DISEASES AND HIV INFECTION Liver diseases ranks as a serious cause of morbidity and mortality in HIV infected persons, whose HIV disease is effectively
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationAntiviral Drugs Advisory Committee Meeting. Briefing Document. Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C NDA
ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 1 Antiviral Drugs Advisory Committee Meeting Briefing Document Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C NDA
More informationNEW ZEALAND DATA SHEET. HARVONI tablets are orange diamond shaped debossed with GSI on one side and the number 7985 on the other side.
NEW ZEALAND DATA SHEET 1 HARVONI (LEDIPASVIR 90 MG, SOFOSBUVIR 400 MG) TABLETS) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ledipasvir 90 mg and sofosbuvir 400 mg) For full list of excipients, see section
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationBruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University
Bruce A. Luxon, MD, PhD, FACG Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University Dr. Luxon is on the speakers p bureau
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationSingle and Multiple Dose Pharmacokinetics and Safety in Non-HIV-Infected Healthy Subjects Dosed with BMS , an Oral HIV Attachment Inhibitor
Single and Multiple Dose Pharmacokinetics and Safety in on-hiv-infected Healthy Subjects Dosed with 66368, an Oral HIV Attachment Inhibitor Richard ettles, Caly Chien, Erica Elefant, Xiaodong Wang, Ellen
More information